Isis Aims High With Lead Diabetes Drug, Still Saddled With Liver Effects
In Phase II data presented at ADA, glucagon receptor antagonist ISIS-GCGR-Rx works well, but increase in liver enzymes persists as warning sign for the class. Nevertheless, Isis thinks the drug will one day step in when oral drugs start to falter – ahead of injectable GLP-1 agonists.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.